摘要
目的 :研究多西他赛 (泰索帝 )每周给药联合顺铂治疗晚期非小细胞肺癌的疗效和不良反应。方法 :多西他赛 35mg/m2 ,每周给药 ,连用 3周休息一周 ,顺铂 75mg/m2 ,每周期的第一天给药。每 2 8天为一个治疗周期。至少 2周期评价疗效。结果 :有 12例患者部分缓解 ,占全部入组病例 (36例 )的 33% ,占可评价病例 (33例 )的 36 % ;中位生存时间 11.5月 (范围 4~ 2 7月 ) ;一年生存率 5 0 %。Ⅲ~Ⅳ度的粒细胞减少为 2 2 % ,非血液系统毒副反应为乏力、指甲毒性及液体潴留。结论 :多西他赛每周给药联合顺铂治疗初治的晚期非小细胞肺癌疗效较好 ,骨髓毒性较轻。
Purpose:To study the efficacy and safety of docetaxel administrated weekly plus cisplatin in the treatment for patients with advanced non-small-cell lung cancer (NSCLC). Methods:Thirty-six patients with stage ⅢB,stage Ⅳ not treated previously by chemotherapy,or recurrenct after operation NSCLC received intravenous infusions of docetaxel at 35mg/m 2 three consecutive weeks,followed by a week of rest;and intravenous infusions of cisplatin at 75 mg/m 2 every four weeks. Results:There were 12 partial responses for an objective response rate of 33 %. The median survival was 11.5 months (range 4-27 months),and the 1-year survival was 50%. Hematologic toxicities,which were mild,included grade Ⅲ/Ⅳ neutropenia in 22%. The common nonhematologic toxicities included grade 2-3 nausea and vomiting (39%) and grade 2-3 asthenia (36%). Conclusions:Consecutive weekly administrations of docetaxel for 3 weeks plus cisplatin produce minimal myelosuppression and shows activity in the treatment of patients without previous chemtherapy with advanced NSCLC.
出处
《中国癌症杂志》
CAS
CSCD
2004年第4期342-344,共3页
China Oncology